The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Use of Tegwondo, a near-continuous temozolomide regimen, in high- and low-grade gliomas.
H. M. Strik
Consultant or Advisory Role - Essex Pharma
Research Funding - Medac
Other Remuneration - Essex Pharma; Medac
H. C. Bock
No relevant relationships to disclose
C. Marosi
No relevant relationships to disclose